However, expression of the anti-PD-L1-scFv results in a strengthening of Onc.Ads therapy because it likely blocks PD-1/PD-L1 interactions, stimulating the IS, and in particular, the T cell population, to recognize and kill cancer cells (Figure 1A). This evidence concerns the gene CD274 and cancer.